Barvarian Nordic has again delayed (slightly) when they expect to have the initial results of the Phase III clinical trial of Prostvac in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development | Tagged: mCRPC, outcome, Prostvac, result, trial | Leave a comment »
Near the end of last month we had told you that data from the LATITUDE trial and from Arm G of the STAMPEDE trial would be presented at the ASCO annual meeting in Chicago this year. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, outcome, trial, Zytiga | Leave a comment »
The Prostate Cancer: Evidence of Exercise and Nutrition Trial (PrEvENT) has been ongoing in England since August 2014 and is an important and serious exploration of how diet and exercise may affect the outcomes of men who are treated for prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: diet, exercise, nutrition, outcome, PrEvent | 2 Comments »
According to an e-mail your sitemaster has just received from ASCO, we will be getting the initial results from the LATITUDE trial at the upcoming ASCO meeting in June this year. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, latitude, outcome, trial | 5 Comments »
The abstract of a paper currently in press in the Journal of Urology has offered us some potentially fascinating insight into the comparative outcomes of patients with low- and higher-risk forms of localized prostate cancer when they are initially managed on active surveillance. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, Management, outcome, risk, surveillance | 4 Comments »
